Calendula

Calendula officinalis flowers contain flavonoids (quercetin, isorhamnetin) and triterpenes with mild sedative and anxiolytic properties, attributed to modulation of GABAergic pathways in animal models. When combined with sedatives or hypnotics, there is a theoretical risk of additive CNS depression, increased sedation, and impaired psychomotor performance, though no clinical cases have been reported.

Caution patients taking sedatives, benzodiazepines, or sleep aids about potential additive drowsiness if taking oral Calendula preparations. Advise against driving or operating heavy machinery if combining. Topical Calendula is unlikely to contribute to systemic CNS effects.

Calendula officinalis demonstrates immunomodulatory activity in vitro and in vivo, including stimulation of macrophage activity, promotion of T-lymphocyte proliferation, and upregulation of pro-inflammatory cytokines (TNF-alpha, IL-1). This immunostimulatory action could theoretically counteract the immunosuppressive effects of cyclosporine, tacrolimus, or azathioprine used in transplant recipients or autoimmune diseases, potentially increasing the risk of organ rejection or disease flare.

Oral Calendula should be used with caution in transplant recipients or patients with autoimmune conditions requiring immunosuppression. Advise healthcare providers of Calendula use. Monitor for signs of organ rejection or autoimmune disease exacerbation. Topical use in these patients is lower risk but should be noted.

Quercetin and isorhamnetin flavonoids found in Calendula officinalis flowers inhibit platelet aggregation through inhibition of thromboxane synthesis and collagen-induced platelet activation, as demonstrated in binding and antiplatelet studies. This mild antiplatelet activity may additively increase bleeding risk when combined with anticoagulants (warfarin) or antiplatelet drugs (aspirin, clopidogrel), particularly at high oral doses.

Monitor for increased bruising or bleeding tendency in patients taking anticoagulants or antiplatelet agents with oral Calendula. Topical preparations are unlikely to contribute to systemic antiplatelet effects. Advise patients to report unusual bleeding. INR monitoring is advisable if oral Calendula is used long-term with warfarin.

In vitro and preclinical studies demonstrate that Calendula officinalis extracts possess hypoglycemic activity, attributed to triterpenoids and flavonoids that may enhance insulin sensitivity and inhibit alpha-glucosidase activity. When combined with oral antidiabetic medications, additive blood glucose lowering effects could theoretically cause hypoglycemia, particularly in patients on insulin or sulfonylureas.

Blood glucose monitoring is advisable in diabetic patients using oral Calendula supplements alongside antidiabetic medications. Patients should be instructed to recognize hypoglycemia symptoms (shakiness, sweating, confusion, palpitations). Adjust antidiabetic dose under medical supervision if hypoglycemia occurs.

Calendula officinalis has demonstrated hypotensive effects in animal models, likely mediated by anti-inflammatory cytokine reduction and vasodilatory flavonoid activity. The triterpenoid and flavonoid constituents may contribute to mild blood pressure lowering that could be additive with antihypertensive medications, potentially causing hypotension especially at higher oral Calendula doses.

Patients taking antihypertensive medications who use oral Calendula supplements should monitor blood pressure periodically. Be alert for symptoms of hypotension (dizziness, lightheadedness on standing, fatigue). Topical Calendula preparations are not expected to cause systemic hypotensive effects.

Calendula officinalis contains triterpenoids (oleanolic acid, ursolic acid, taraxasterol), flavonoids (quercetin, isorhamnetin), and carotenoids that collectively inhibit COX-1 and COX-2 enzymatic activity and downstream prostaglandin synthesis. Combined with NSAIDs (which also inhibit COX enzymes), the anti-inflammatory effect may be additive, which can be beneficial clinically but also additively increases gastrointestinal mucosal irritation risk. Calendula triterpenoids have also shown anti-oedema activity comparable to indomethacin in preclinical models.

The combination of oral calendula with NSAIDs is low-risk but monitor for GI adverse effects (nausea, dyspepsia, gastric irritation). Topical calendula preparations co-used with systemic NSAIDs pose negligible systemic interaction risk. If anti-inflammatory properties are sought clinically, consider whether one agent alone is sufficient rather than combining both.

Calendula officinalis is used in oncology settings (topically) for radiation-induced dermatitis. A Phase III randomised trial (Pommier et al. 2004) compared Calendula cream to trolamine for acute dermatitis in breast cancer patients receiving radiation therapy — Calendula reduced grade 2+ acute dermatitis (41% vs 63%). However, calendula saponins and flavonoids also have cytotoxic properties in vitro that may theoretically interact with systemic chemotherapy agents if taken orally. Oral consumption near chemotherapy administration may create unpredictable interactions.

Topical calendula is considered safe and potentially beneficial for radiation-induced skin reactions in oncology. Oral calendula supplements during systemic chemotherapy should be discussed with the oncology team first. Discontinue oral calendula supplements at least 2 weeks before starting chemotherapy. Topical use around radiation ports is acceptable per clinical trial evidence.

Calendula officinalis has demonstrated sedative properties in animal models, extending pentobarbital-induced sleeping time and producing anxiolytic effects in preclinical studies. The mechanism may involve GABAergic modulation by flavonoids (quercetin, isoquercitrin) or terpenoids. When combined with pharmaceutical sedatives or hypnotics, additive CNS depression and sedation may result. This interaction is relevant for oral Calendula preparations used medicinally at higher doses.

Advise patients taking sedative medications (benzodiazepines, z-drugs, melatonin, antihistamines) to use calendula with caution, particularly oral preparations. Monitor for excessive sedation. Topical calendula products carry negligible systemic CNS risk. This interaction is of greatest concern with high-dose oral Calendula extracts.